Daniel Waid Marshall
Good night. I am Daniel Marshall, Senior Supervisor of Communications and Possession. I am joined by Jason Kelly, our Co-Founder and CEO; and Steve Coen, our CFO. Thanks, as at all times, for becoming a member of us. We’re wanting ahead to updating you on our progress.
As a reminder, throughout the presentation at this time, we shall be making forward-looking statements, which contain dangers and uncertainties. Please confer with our filings with the SEC to be taught extra about these dangers and uncertainties, together with our most up-to-date 10-Ok.
Right this moment, along with updating you on the quarter outcomes, we will present perception into the autonomous lab, how we imagine it is going to rework biotechnology and the way we plan to commercialize autonomous labs going ahead.
As typical, we’ll finish with a Q&A session, and I am going to take questions from analysts, buyers and the general public. You’ll be able to submit these inquiries to us upfront through X, #ginkgoresults or via e-mail, buyers@ginkgobioworks.com. All proper. Over to you, Jason.
Jason Kelly
Co-Founder, Co-COO, CEO & Director
All proper. Thanks, Daniel. So This autumn was actually a breakout quarter for us in kind of defining and actually main within the class of autonomous labs. And so you are going to hear loads from me about that sooner or later. However I wish to begin by saying our mission stays to make biology simpler to engineer. However in 2026, the technological focus for the corporate and actually the enterprise focus goes to drill down on investing to win on this class of autonomous labs. And that is actually part of what I see as an rising motion round robotics and AI and autonomy that is coming to
